Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Tofacitinib 11mg Tablet
Therapeutic Category
Anti-Inflammatories, Immunology, Rheumatology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹590/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Tofatake ER 11 Tablet contains Tofacitinib 11mg in an extended-release formulation. Tofacitinib is a Janus kinase (JAK) inhibitor that modulates immune response by inhibiting JAK1 and JAK3 enzymes, which play a key role in the pathogenesis of inflammatory and autoimmune diseases. The extended-release version provides sustained drug levels over 24 hours, allowing for once-daily dosing, improving patient compliance and maintaining therapeutic efficacy throughout the day.
Tofatake ER 11 is indicated in the management of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, especially in patients who have had an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (DMARDs).
Common side effects may include headache, diarrhea, nasopharyngitis, and hypertension. Serious risks include increased risk of infections, blood clots, elevated liver enzymes, and changes in blood lipid levels. Regular monitoring is recommended.
Tofatake ER 11 Tablet is indicated for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis who have not responded adequately to previous DMARDs or biologic therapies. It helps reduce joint pain, stiffness, inflammation, and improves physical function in autoimmune conditions by controlling abnormal immune responses.
Use only under supervision of a specialist. Not recommended for use in patients with active serious infections, liver impairment, or those on strong immunosuppressants. Routine CBC, LFT, and lipid profile monitoring is advised during therapy.
Store in a cool, dry place away from direct sunlight.
Composition : Cefpodoxime Proxetil (100mg/5ml)
Composition : Cefixime (100mg/5ml)
Composition : Cefalexin (125mg)
Composition : Clarithromycin (125mg)
Composition : Cefixime (50mg/5ml)
Composition : Cefuroxime (125mg)
Composition : Cefpodoxime Proxetil (50mg) + Clavulanic Acid (31.25mg)
Composition : Cefpodoxime Proxetil (100mg) + Clavulanic Acid (62.5mg)
Composition : Cefixime (50mg/5ml) + Clavulanic Acid (31.25mg/5ml)
Composition : Cefuroxime (125mg) + Clavulanic Acid (31.25mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Tofacitinib Tablets have strong demand in the rheumatology and immunology segment, making them a premium specialty product for pharma distributors, wholesalers, and franchise partners. It is widely used for rheumatoid arthritis, psoriatic arthritis, and other autoimmune inflammatory conditions, ensuring steady long-term prescription demand under specialist supervision.
Medical distributors and agencies benefit from the growing demand for advanced autoimmune and biologic-like oral therapies. Belongs to JAK inhibitor class for autoimmune diseases Used in rheumatoid arthritis and psoriatic arthritis management Prescribed by rheumatologists and specialist physicians Oral alternative to some injectable biologic therapies Important in chronic long-term disease management Increasing adoption in specialty and tertiary care hospitals This makes it a high-value specialty medicine with strong long-term prescription retention.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Tofacitinib 11 mg Tablets with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and franchise partners benefit from high-value specialty prescription demand, long-term chronic therapy usage, strong hospital and specialist-driven sales, and stable premium-margin turnover in the autoimmune segment.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete specialty and autoimmune product portfolio access to build a strong presence in the rheumatology and immunology market.